Abstract:Schematic illustration of engineering a bispecific nanobody‐based nanotherapy for targeted treatment of inflammatory bowel disease (IBD). (A) Development of the anti‐TNF‐α & IL‐23 bispecific nanobody (BsNb) and its quadrivalent structure (BsNb‐Fc). The BsNb and BsNb‐Fc were constructed and screened, demonstrating high affinity and stability. (B) Mechanism of targeted therapy of colitis by BsNb‐Fc. The nanocarrier of BsNb‐Fc exhibits intrinsic adhesive capability and penetrates the destructed intestinal barrier to target the inflamed colon. BsNb‐Fc binds to the membrane‐bound TNF‐α (mTNF‐α) and IL‐23 secreted by macrophages, effectively blocking the TNF/TNFR and IL‐23/IL23R cell signaling pathways in TNFR2+IL23R+CD4+ T cells. This disruption leads to the suppression of CD4+ T cell proliferation and differentiation and induces apoptosis, thereby alleviating intestinal mucosal inflammation. The therapeutic strategy shows promise for IBD patients unresponsive to anti‐TNF‐α therapy. Background Inflammatory bowel diseases (IBDs) pose significant challenges in terms of treatment non‐response, necessitating the development of novel therapeutic approaches. Although biological medicines that target TNF‐α (tumour necrosis factor‐α) have shown clinical success in some IBD patients, a substantial proportion still fails to respond. Methods We designed bispecific nanobodies (BsNbs) with the ability to simultaneously target human macrophage‐expressed membrane TNF‐α (hmTNF‐α) and IL‐23. Additionally, we fused the constant region of human IgG1 Fc (hIgG1 Fc) to BsNb to create BsNb‐Fc. Our study encompassed in vitro and in vivo characterization of BsNb and BsNb‐Fc. Results BsNb‐Fc exhibited an improved serum half‐life, targeting capability and effector function than BsNb. It's demonstrated that BsNb‐Fc exhibited superior anti‐inflammatory effects compared to the anti‐TNF‐α mAb (infliximab, IFX) combined with anti‐IL‐12/IL‐23p40 mAb (ustekinumab, UST) by Transwell co‐culture assays. Notably, in murine models of acute colitis brought on by 2,4,6‐trinitrobenzene sulfonic acid(TNBS) and dextran sulphate sodium (DSS), BsNb‐Fc effectively alleviated colitis severity. Additionally, BsNb‐Fc outperformed the IFX&UST combination in TNBS‐induced colitis, significantly reducing colon inflammation in mice with colitis produced by TNBS and DSS. Conclusion These findings highlight an enhanced efficacy and improved biostability of BsNb‐Fc, suggesting its potential as a promising therapeutic option for IBD patients with insufficient response to TNF‐α inhibition. Key points A bispecific nanobody (BsNb) was created to target TNF‐α and IL‐23p19, exhibiting high affinity and remarkable stability. BsNb‐Fc inhibited the release of cytokines in CD4+T cells during co‐culture experiments. BsNb‐Fc effectively alleviated colitis severity in mouse model with acute colitis induced by DSS or TNBS, outperforming the IFX&UST combination.

Dominant-negative Tumor Necrosis Factor Protects from Mycobacterium Bovis Bacillus Calmette Guérin (BCG) and Endotoxin-Induced Liver Injury Without Compromising Host Immunity to BCG and Mycobacterium Tuberculosis.

Dominant negative biologics normalise the tumour necrosis factor (TNF-α) induced angiogenesis which exploits the Mycobacterium tuberculosis dissemination

Vaccine targeting TNF epitope 1–14 do not suppress host defense against Mycobacterium bovis Bacillus Calmette-Guérin infection

Tumour Necrosis Factor Alpha (tnfα) Vaccines in the Downregulation of Bowel Inflammatory Responses in Mice

Cutting Edge: TNF Is Essential for Mycobacteria-Induced MINCLE Expression, Macrophage Activation, and Th17 Adjuvanticity

TNF in Human Tuberculosis: A Double-Edged Sword

TNF-dependent regulation and activation of innate immune cells are essential for host protection against cerebral tuberculosis

TNF biology, pathogenic mechanisms and emerging therapeutic strategies

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents)

Protective role of tumor necrosis factor (TNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response

TNF Receptor 1 Promotes Early-Life Immunity and Protects Against Colitis in Mice.

The effect of TNF on the colonic microbiome and acute colitis (650.11)

Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

Antisense Oligonucleotides Against TNFR1 Prevent Toxicity of TNF/IFNγ Treatment in Mouse Tumor Models

Protective Effect of a Novel Antibody Against TLR2 on Zymosan-Induced Acute Peritonitis in NF-κB Transgenic Mice.

Opposite Role Of Tumor Necrosis Factor Receptors In Dextran Sulfate Sodium-Induced Colitis In Mice

Death by TNF: a road to inflammation

Tuberculosis in otherwise healthy adults with inherited TNF deficiency

Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF‐α and IL‐23p19 bioactivities

Unleashing endogenous TNF-alpha as a cancer immunotherapeutic

A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer